Antidotes to anthrax lethal factor intoxication. Part 2: Structural modifications leading to improved in vivo efficacy

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 7, 2011, Pages 2030-2033

  Kim, Seongjin ^a   Jiao, Guan Sheng ^a   Moayeri, Mahtab ^b   Crown, Devorah ^b   Cregar Hernandez, Lynne ^a   McKasson, Linda ^a   Margosiak, Stephen A ^a   Leppla, Stephen H ^b   Johnson, Alan T ^a  

^a PanThera Biopharma LLC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax; Inhibitor; Lethal factor; Small molecule

Indexed keywords

3 METHYL 4 FLUORO PHENOXYACETIC ACID; ANTHRAX TOXIN; ANTIDOTE; ANTIINFECTIVE AGENT; ETHYL 2 BROMOACETATE; LETHAL FACTOR INHIBITOR; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANTHRAX; ARTICLE; DRUG EFFICACY; DRUG INTOXICATION; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDOTES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; MOLECULAR STRUCTURE; POISONING; RATS;

RATTUS;

EID: 79952489032     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.010     Document Type: Article

References (16)

1. Friedlander, A. M. In Medical Aspects of Chemical and Biological Warfare; Sidell, F. R., Takafuji, E. T., Franz, D. R., Eds.; TMM Publications: Washington D.C., 1997; 13, p 467. Chapter 22.
2. Jernigan, J. A.; Stephens, D. S.; Ashford, D. A.; Omenaca, C.; Topiel, M. S.; Galbraith, M., et al Emerg. Infect. Diseases 2001, 7, 933.
3. Moayeri, M.; Leppla, S. H. Mol. Aspects Med. 2009, 30, 439.
4. (a) Klein, F.; Hodges, D. R.; Mahlandt, B. G.; Jones, W. I.; Haines, B. W.; Lincoln, R. E. Science 1962, 138, 1331;
5. (b) Pezard, C.; Berche, P.; Mock, M. Infect. Immun. 1991, 59, 3472.
6. Shoop, W. L.; Xiong, Y.; Wiltsie, J.; Woods, A., et al Proc. Natl. Acad. Sci. U.S.A 2005, 102, 7958.
7. For more information regarding the use of this rule see: US FDA Guidance for Industry. Animal Models - Essential Elements to Address Efficacy Under the Animal Rule. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf
8. Newman, Z. L.; Printz, M. P.; Li, S.; Crown, D.; Breen, L.; Miller-Randolph, S.; Flodman, P.; Leppla, S. H.; Moayeri, M. PLoS Pathog. 2010, 6, e1000906.
9. Jiao, G.-S.; Kim, S.; Moayeri, M.; Cregar-Hernandez, L.; McKasson, L.; Margosiak, S. A.; Leppla, S. H.; Johnson, A. T. Bioorg. Med. Chem. Lett. 2010, 20, 6850.
10. Synthetic routes to compounds 3a, 5a, 13, 14, 15, and 16, along with protocols for the biochemical and in vivo assays, and survival curves for the data given in Tables 3 and 4 are provided as Supplementary Material.
11. Johnson, A.; Jiao, G.-S.; Kim, S. WO 2009/008905 A1.
12. Evans, D. A.; Ennis, M. D.; Mathre, D. J. J. Am. Chem. Soc. 1982, 104, 1737.
13. Turk, B. E.; Wong, T. Y.; Schwarzenbacher, R.; Jarrell, E. T.; Leppla, S. H.; Collier, R. J.; Liddington, R. C.; Cantley, L. C. Nature Struct. Mol. Biol. 2004, 11, 60.
14. Overton, J. P.; Al-Lazikani, B.; Hopkins, A. L. Nat. Rev. Drug Discovery 2006, 5, 993.
15. Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. In Methods and Principles in Medicinal Chemistry; Mannhold, R., Kubinyi, H., Timmerman, H., Eds.; Wiley-VCH GmbH: Weinheim, 2001; 13, pp 78-80.
16. Venhorst, J.; ter Laak, A. M.; Commandeur, J. N. M.; Funae, Y.; Hiroi, T.; Vermeulen, N. P. E. J. Med. Chem. 2003, 46, 74.